Recombinant Alpha-Galactosidase A
Fabry Disease
Shireprotein_peptidePhase 4 / ApprovedActive
A
84/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 81/ 100
- Competitive Position
- 89/ 100
Competitive context
22 Active assets in the Fabry Disease cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Agalsidase Beta Sanofi | Phase 4 | A |
Pegunigalsidase Alfa Chiesi Italia | Phase 3 | A |
Migalastat Amicus Therapeutics | Phase 3 | BBB |
Loratadine Sanofi | Phase 4 | BB |
Montelukast Sanofi | Phase 4 | BB |
View all 37 →
Same molecule, other indications
Recombinant Alpha-Galactosidase A is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →